These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28954880)

  • 21. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.
    Li Y; Hu Y; Ley SH; Rajpathak S; Hu FB
    Diabetes Care; 2014 Nov; 37(11):3106-13. PubMed ID: 25150157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
    Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
    Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin and the risk of endometrial cancer: a population-based cohort study.
    Ko EM; Stürmer T; Hong JL; Castillo WC; Bae-Jump V; Funk MJ
    Gynecol Oncol; 2015 Feb; 136(2):341-7. PubMed ID: 25499603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
    Yu O; Azoulay L; Yin H; Filion KB; Suissa S
    Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
    Calip GS; Yu O; Elmore JG; Boudreau DM
    Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
    Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
    Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
    J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical therapy for diabetes is associated with increased use of lower endoscopy.
    Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1195-202. PubMed ID: 17603822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
    Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
    Johnson JA; Majumdar SR; Simpson SH; Toth EL
    Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
    Shi Q; Liu S; Fonseca VA; Thethi TK; Shi L
    BMJ Open; 2019 Jul; 9(7):e024954. PubMed ID: 31366635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
    Bowker SL; Lin M; Eurich DT; Johnson JA
    Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH; Yin H; Azoulay L
    Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort study.
    Hung AM; Hackstadt AJ; Griffin MR; Grijalva CG; Greevy RA; Roumie CL
    CMAJ Open; 2023; 11(1):E77-E89. PubMed ID: 36720491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
    Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM
    Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.